论文部分内容阅读
历时 4年多的EUROPA ,即培哚普利在稳定型冠心病患者中降低心血管事件的欧洲试验的结果在欧洲心脏学会第 2 5届年会上正式公布。EUROPA主要是评价ACE抑制剂培哚普利减少不伴心力衰竭的稳定型冠心病患者心脏事件的长期 (4年 )疗效 ,是迄今针对稳定型冠心病患者规模最大的研究。
The results of the European trial of EUROPA, perindopril, which reduces cardiovascular events in patients with stable coronary artery disease for more than four years, was officially announced at the European Society of Cardiology’s 25th annual meeting. The main purpose of EUROPA is to evaluate the long-term (4-year) efficacy of the ACE inhibitor perindopril in reducing cardiac events in patients with stable coronary heart disease without heart failure and is by far the largest study in patients with stable coronary heart disease.